Bulletin
Investor Alert

London Markets Open in:

Biogen Inc.

NAS: BIIB

GO
/marketstate/country/us

After Hours

/zigman2/quotes/201531540/composite

$

294.14

Change

0.00 0.00%

Volume

Volume 54,792

Nov 11, 2019, 4:42 p.m.

Quotes are delayed by 20 min

/zigman2/quotes/201531540/composite

Previous close

$ 293.25

$ 294.14

Change

+0.89 +0.30%

Day low

Day high

$290.52

$294.92

Open
Open: 292.48

52 week low

52 week high

$215.78

$344.00

Open

Market cap

$53.08B

Average volume

2.26M

P/E ratio

10.46

Rev. per Employee

$1.55M

EPS

28.12

Dividend

N/A

Div yield

N/A

Ex dividend date

N/A

Compare:
Indexes
  • Dow(INDU) INDU
  • Nasdaq (COMP) COMP
  • S&P 500 (SPX) SPX
  • Global Dow (GDOW) GDOW
1d
5d
3m
6m
1y
3y
5y
/news/latest/company/us/biib

MarketWatch News on BIIB

  1. Biogen ups investment in biosimilars

    8:20 a.m. Nov. 6, 2019

    - Jaimy Lee

  2. Biogen to book charge of about $65 mln once biosimilar deal closes

    7:52 a.m. Nov. 6, 2019

    - Ciara Linnane

  3. Biogen to buy biosimilar rights to Lucentis and Eylea, to pay $100 mln upfront

    7:51 a.m. Nov. 6, 2019

    - Ciara Linnane

  4. Biogen upgraded to outperform at Bernstein

    2:33 p.m. Oct. 30, 2019

    - Tomi Kilgore

  5. Biogen, Alkermes MS treatment Vumerity gets FDA approval

    7:33 a.m. Oct. 30, 2019

    - Tomi Kilgore

  6. Biogen upgraded to outperform from market perform at SVB Leerink

    8:23 a.m. Oct. 23, 2019

    - Tomi Kilgore

  7. Earnings Season Racks Up More Winners and Losers

    1:00 p.m. Oct. 22, 2019

    - Ben Walsh

  8. Biogen Stock Could Have Run Up Too Far on Alzheimer’s Drug Revival

    11:48 a.m. Oct. 22, 2019

    - Josh Nathan-Kazis

  9. Biogen Stock Is Soaring as Hope Returns for Alzheimer’s Drug

    10:48 a.m. Oct. 22, 2019

    - Josh Nathan-Kazis

  10. Loading more headlines...

Analyst Ratings

/news/nonmarketwatch/company/us/biib

Other News on BIIB

  1. Roche's Gazyva successful in mid-stage lupus nephritis study

    10:06 a.m. Nov. 11, 2019

    - Seeking Alpha

  2. 4 Biotech Stocks That Could Keep Beating Wall Street

    9:28 a.m. Nov. 11, 2019

    - Zacks.com

  3. Sell Biogen Going Into Its Aducanumab BLA Filing

    2:05 p.m. Nov. 8, 2019

    - Seeking Alpha

  4. Pharma Sector Tops in October: Best ETFs & Stocks

    8:00 a.m. Nov. 8, 2019

    - Zacks.com

  5. Biogen Is A Buy Regardless Of Aducanumab

    3:15 p.m. Nov. 6, 2019

    - Seeking Alpha

  6. Biogen expands biosimilar relationship with Bioepis

    8:20 a.m. Nov. 6, 2019

    - Seeking Alpha

  7. Biotech ETFs in Focus on Impressive Q3 Earnings Results

    5:05 p.m. Nov. 4, 2019

    - Zacks.com

  8. Boston nonprofit playing big role in drug pricing

    1:44 p.m. Nov. 4, 2019

    - Seeking Alpha

  9. Boston nonprofit playing big role in drug pricing

    1:43 p.m. Nov. 4, 2019

    - Seeking Alpha

  10. Boston nonprofit playing big role in drug pricing

    1:43 p.m. Nov. 4, 2019

    - Seeking Alpha

  11. Boston nonprofit playing big role in drug pricing

    1:43 p.m. Nov. 4, 2019

    - Seeking Alpha

  12. Value Biotech ETFs & Stocks to Buy Now

    1:00 p.m. Nov. 4, 2019

    - Zacks.com

  13. Biogen And Eisai's Aducanumab: All That Glitters Is Not Gold

    11:24 a.m. Nov. 4, 2019

    - Seeking Alpha

  14. Biotech Value Stocks Climb Out of Sick Bed

    10:16 a.m. Nov. 2, 2019

    - Charley Grant

  15. The Good, Bad, and Ugly for Biogen Stock

    2:16 p.m. Nov. 1, 2019

    - InvestorPlace.com

  16. Healthcare ETF (IHF) Tops in October: 5 Best Stocks

    12:00 p.m. Nov. 1, 2019

    - Zacks.com

  17. Loading more headlines...
/news/pressrelease/company/us/biib

Press Releases on BIIB

  1. Alpha Synuclein Market Competitive Analysis With Growth Forecast Till 2025

    8:35 a.m. Nov. 8, 2019

    - Market Insight Reports

  2. Asuragen Announces Launch of AmplideX® PCR/CE SMN1/2 Plus Kit

    8:00 a.m. Nov. 6, 2019

    - BusinessWire - BZX

  3. Liver Fibrosis Drug Market Size, Status and Forecasts 2025

    10:56 p.m. Nov. 4, 2019

    - Market Insight Reports

  4. Kura Oncology Appoints James Basta as Chief Legal Officer

    7:30 a.m. Nov. 4, 2019

    - GlobeNewswire

  5. Loading more headlines...

Rates »

Link to MarketWatch's Slice.